FAQ

zanolimumab

Known as: Anti-CD4 Monoclonal Antibody HuMax, HuMax-CD4 
A human IgG1k monoclonal antibody against the CD4 receptor on T-lymphocytes, with potential antineoplastic and immunosuppressing activities… (More)
National Institutes of Health

Topic mentions per year

Topic mentions per year

2003-2016
024620032016

Related topics

Related topics

2 relations

Broader (1)

Monoclonal Antibodies
antigen binding

Related mentions per year

Related mentions per year

1948-2018
19401960198020002020
zanolimumab
Monoclonal Antibodies
antigen binding

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2011
2011
Molecular evidence of a genotypically novel large T-cell lymphoma after anti-CD4 therapy for refractory mycosis fungoides.
Zanolimumab, a human monoclonal antibody against CD4 isolated from human antibody transgenic mice, has been shown to have a high… (More)
  • figure 1
  • table I
Is this relevant?
2010
2010
Phase II trial of zanolimumab (HuMax-CD4) in relapsed or refractory non-cutaneous peripheral T cell lymphoma.
The efficacy and safety of zanolimumab (HuMax-CD4) in patients with relapsed or refractory peripheral T Cell lymphoma (PTCL) was… (More)
Is this relevant?
Review
2008
Review
2008
Zanolimumab, a human monoclonal antibody targeting CD4 in the treatment of mycosis fungoides and Sézary syndrome.
BACKGROUND The most common type of primary cutaneous T cell-lymphomas (CTCLs), which are characterised by a clonal proliferation… (More)
Is this relevant?
2007
2007
Clinical efficacy of zanolimumab (HuMax-CD4): two phase 2 studies in refractory cutaneous T-cell lymphoma.
The efficacy and safety of zanolimumab in patients with refractory cutaneous T-cell lymphoma (CTCL) have been assessed in two… (More)
  • table 1
  • table 2
  • table 3
  • table 4
  • figure 2
Is this relevant?
2007
2007
Drug evaluation: zanolimumab, a human monoclonal antibody targeted against CD4.
Merck Serono SA, under license from Genmab A/S and Medarex Inc, is developing zanolimumab, a human mAb targeted against CD4, for… (More)
Is this relevant?
2007
2007
A human CD4 monoclonal antibody for the treatment of T-cell lymphoma combines inhibition of T-cell signaling by a dual mechanism with potent Fc-dependent effector activity.
Zanolimumab is a human IgG1 antibody against CD4, which is in clinical development for the treatment of cutaneous and nodal T… (More)
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
Is this relevant?
Review
2007
Review
2007
Systemic monotherapy vs combination therapy for CTCL: rationale and future strategies.
There are few approved therapies for cutaneous T-cell lymphoma (CTCL). The retinoids are the major biologic response modifiers… (More)
Is this relevant?
2006
2006
In situ depletion of CD4+ T cells in human skin by Zanolimumab
CD4+ T cells, in activated or malignant form, are involved in a number of diseases including inflammatory skin diseases such as… (More)
  • figure 1
  • figure 2
  • figure 3
Is this relevant?
2005
2005
Treatment of a patient with a nodal peripheral T-cell lymphoma (angioimmunoblastic T-Cell lymphoma) with a human monoclonal antibody against the CD4 antigen (HuMax-CD4).
A patient with a CD4+ refractory peripheral T-cell lymphoma (PTL), subtype angioimmunoblastic T-cell lymphoma (AILD), was treated… (More)
Is this relevant?
2003
2003
HuMax-CD4: a fully human monoclonal anti-CD4 antibody for the treatment of psoriasis vulgaris.
BACKGROUND Psoriasis is characterized by infiltration with mononuclear cells. Especially activated memory CD4+ T cells are… (More)
  • table 1
  • table 2
  • figure 1
  • figure 2
  • figure 3
Is this relevant?